Results of Surveying Cardiologists and Clinical Pharmacologists on the Selection and the Efficacy and Safety Evaluation of Pharmacotherapy for Cardiovascular Diseases

The state policy for the safety of medicinal products involves analysis of specialists' competence in identifying adverse drug reactions (ADRs) during the use of medicinal products. It is of particular importance for the group of essential medicines, including those used in cardiology.

The aim of the study was to assess ADR-reporting skills of doctors managing cardiology patients, with anti-arrhythmics as a case study.

Materials and methods: from October 2019 to June 2021, the authors surveyed a sample of 223 practitioners that treated cardiology patients in Moscow and the Moscow region (36 of the respondents took the survey in person, and 187 participated on-line). The questionnaire inquired about selection criteria for the medicinal products, their assessment in terms of efficacy and safety in real-life clinical practice, and the competence and active involvement of the doctors in reporting identified ADRs.

Results: most of the survey participants were high-level professionals (60.99% had 10 and more years of experience). Most of the doctors (90.13%) admitted having encountered ADRs in their practice, placing substandard quality of cardiovascular medicinal products among the causes. Moreover, 1.79% of the respondents faced such quality problems on a regular basis. Only 52.91% were familiar with the current documents regulating pharmacovigilance. A total of 61.88% applied information from Russian and foreign ADR databases in their practice. In 2021, 80.72% of the surveyed did not report data on the identified ADRs. According to the respondents, the main reasons for low reporting activity were high workload and lack of evidence for causality between a product and an ADR.

Conclusion: the study demonstrated the need to intensify the work with practitioners on the safety of medicinal products and ADR identification, particularly, to train them in pharmacovigilance. According to the study results, it is feasible to develop and implement simple and user-friendly risk-oriented information systems for analysis and systematisation of ADR case reports.

1. Babenko AYu, Dry RV, Karonova TL, Makarenko IE. Evidence-based approaches for development and marketing authorization of diabetes drugs. RMZh = RMJ. 2018;26(1):48-54 (In Russ.)

2. Smuseva ON, Gorbatenko VS, Solovkina YuV, Shatalova OV. Effective monitoring of drug safety in the region. Saratovskiy nauchno-meditsinskiy zhurnal = Saratov Journal of Medical Scientific Research. 2012;8(4):910-4 (In Russ.)

3. Konradi AO, Polu-nicheva EV. Inadequate compliance in the treatment of arterial hypertension: causes and ways of correction. Arterial'naya gipertenziya = Arterial Hypertension. 2004;10(3):137-43 (In Russ.)

4. Zyryanov SK, Ivzhits MA, Ivanov DA. The monitoring of drug use safety in the multispeciality hospital. Khirurg = Surgeon. 2018;(5-6):73-9 (In Russ.)

5. Krasheninnikov AE, Romanov BK, Safiullin RS. Problem of insufficient involvement of the population into phar-macovigilance system. Permskiy meditsinskiy zhurnal = Perm Medical Journal. 2018;35(4):50-5 (In Russ.) https://doi.org/10.17816/pmj35450-55

6. Murashko MA, Parhomenko DV, Asetskaya IL, Kosenko VV, Polivanov VA, Glagolev SV. The role and practice of pharmacovigilance in Russian healthcare. Vestnik Roszdravnadzora = Bulletin of Roszdravnadzor. 2014;(3):54-61 (In Russ.)

7. Khoseva EN, Morozova TE, Andrushchishina TB. Awareness of general practitioners about the safety of drug therapy. In: Collection of materials of the XV International Scientific and Practical Conference «Military and political sciences in the context of social progress». Odessa: InPress; 2012. P. 123-5 (In Russ.)

8. Seydarypkyzy A, Zhetpisbayeva AK, Bazarbekova AN, Mukhamedzhanova A, Patullayeva Zh, Doskalieva A, et al. Quality of life of patients with fibrillation of precurities. Vestnik Kazakhskogo natsionalnogo meditsinskogo universiteta = Bulletin of Kazakh National Medical University. 2017;(3):78-82 (In Russ.)

9. Olefir YuV, Verlan NV, Romanov BK, Dvoynikova NA, Kochkina EO. Problems of monitoring the safety of pharmacotherapy. Moscow: Folium; 2017 (In Russ.)

10. Matveev AV, Krasheninnikov AE, Egorova EA. On-line monitoring of electronic resources in the activities of the qualified person responsible for pharmacovigilance. Remedium = Remedium. 2018;(7-8):60-4 (In Russ.)